CT-G32 vs Retatrutide

    CT-G32 (also SCO-940) is the first publicly disclosed single molecule built to act on four receptors: GLP-1, GIP, glucagon and amylin. Retatrutide (LY3437943) acts on the first three and has published phase 3 results. CT-G32 has only been tested in animals, with its first data shown in November 2026. This page compares them as research compounds.

    Available at Peptx

    Retatrutide

    UK single vials

    View

    Retalora

    Retatrutide 10mg + Eloralintide 2.5mg

    View

    Supplied for in-vitro research only.

    Development code
    CT-G32 (SCO-940)LY3437943
    Receptor targets
    GLP-1, GIP, glucagon and amylin (four)GLP-1, GIP and glucagon (three)
    Molecule
    One molecule acting on all fourOne peptide acting on all three
    Evidence so far
    Obese rats and primate blood-level studies, company-reportedPhase 3 trials in people, published
    Headline result
    Numerically greater weight loss than retatrutide in obese rats at the same molar doseTRIUMPH-1: 17.6% to 25.0% at 80 weeks, placebo 3.9%
    Status
    Preclinical; a US trial application is planned by February 2027Phase 3; a US filing is planned for early 2027
    Peptx availability
    Not availableUK single vials and Factory Direct kits

    Three receptors or four

    Retatrutide combines activity at the GLP-1 and GIP receptors, the pair tirzepatide acts on, with activity at the glucagon receptor. CT-G32 keeps those three and adds the amylin receptor, the target of cagrilintide, eloralintide and petrelintide.

    Amylin is a separate hormone system from the incretins. Until now it has been added as a second molecule alongside an incretin compound, as with cagrilintide and semaglutide, or eloralintide and tirzepatide. CT-G32 is the first disclosed attempt to put amylin and all three of retatrutide's targets into one molecule.

    What the first data showed, and what it did not

    The first CT-G32 results were presented at the TIDES Europe conference in Amsterdam on 3 to 5 November 2026. In diet-induced obese rats, the developers reported numerically greater weight loss than retatrutide at the same molar dose, a smaller share of the lost weight coming from lean mass, and lower insulin levels. In primates the compound stayed in the blood long enough to support a once-weekly form.

    These are company-reported animal results from a conference, not a peer-reviewed paper. No figures or statistical tests were published with the announcement, and "numerically greater" does not mean the difference was shown to be reliable. CT-G32 has not been given to people, so nothing is known about how it is tolerated.

    Retatrutide's record is of a different kind. TRIUMPH-1, published in the New England Journal of Medicine in September 2026, enrolled 2,339 adults and reported weight reductions of 17.6%, 23.7% and 25.0% at 80 weeks, against 3.9% on placebo.

    Four receptors with two molecules

    The same four receptors can be covered in the laboratory today with two separate compounds: retatrutide for GLP-1, GIP and glucagon, and a selective amylin agonist such as eloralintide for the fourth. Peptx supplies the two as single vials and as Retalora, a research blend of Retatrutide 10mg and Eloralintide 2.5mg in one vial.

    A blend of two molecules is not a quad agonist, and no published study has tested retatrutide and eloralintide together. The two components can differ in how strongly and for how long each acts, which a single molecule fixes by design.

    Bottom line for research labs

    CT-G32 is the first single molecule to add amylin to retatrutide's three targets, and its first rat data compared well with retatrutide. It is still an animal-stage candidate with no published figures. Retatrutide remains the multi-receptor reference with phase 3 data. Labs studying what the amylin arm adds to a triple agonist currently work with retatrutide and a separate amylin agonist.

    Frequently asked questions

    What is CT-G32?▼
    CT-G32, also called SCO-940, is a preclinical obesity candidate from Celltrion and SCOHIA PHARMA. It is a single molecule designed to act on four receptors: GLP-1, GIP, glucagon and amylin.
    Did CT-G32 beat retatrutide?▼
    Only in one animal comparison reported by its developers. In diet-induced obese rats, CT-G32 produced numerically greater weight loss than retatrutide at the same molar dose. No figures or statistics were published, and it has not been tested in people.
    When will CT-G32 be tested in people?▼
    Celltrion has said it aims to submit a US trial application by February 2027 and to start a first study in people after that. As of November 2026 no human study has begun.
    Is CT-G32 the same as NA-931?▼
    No. Both are described as acting on four receptors, but different ones. NA-931 is described as acting on the IGF-1, GLP-1, GIP and glucagon receptors. CT-G32 acts on GLP-1, GIP, glucagon and amylin.
    Is Retatrutide plus Eloralintide a quad agonist?▼
    No. A quad agonist is one molecule acting on four receptors. Retatrutide and Eloralintide are two molecules that between them act on the same four receptors as CT-G32. No published study has tested the two together.
    Can I buy CT-G32 from Peptx?▼
    No. CT-G32 is a company development candidate and Peptx does not supply it. Retatrutide is available as UK single vials and Factory Direct kits, and Retalora (Retatrutide 10mg with Eloralintide 2.5mg) as a UK single vial. Both are for in-vitro research only.